Company environment · Antibody-drug conjugates · Korea MFDS
A cancer drug’s first approval in Korea
Just approved in Korea; preparing launch. Start at the top to see what the company does, then the jobs AI models were given here and how each scored.
1What does this company do?
The Korean branch of a global drug company.
It handles the Korean approval and launch of a drug already approved elsewhere.
2Where is the product on its way to patients?
An antibody that carries chemotherapy into cancer cells, just approved in Korea for the first time.
- 1Discovery
- 2Lab & animal studies
- 3Human trials
- 4Filing & review
- 5Approved
- The product is here
- 6On the market
The branch must close out the approval file and hand over to launch, using only what was known on that date.
3What is happening right now?
It is 19 September 2022, the day of first approval; the launch handoff is tomorrow.
Colleagues say several packs are “assembled”. Each job checks whether they really are, against the evidence on file.
4Which jobs were the models given?
7 jobs, each graded against a specialist’s checklist.
Scores are checks passed out of checks in the list. Each model ran each job once.
5–7Evidence, work and verdict
This company’s files stay private.
It is built from a real product’s records, so its files, runs and checklists aren’t published. To follow a job all the way down to each check, open one of the public environments.
Havenor Therapeutics (fictional, fully published) →
Broad Institute (real, public FDA record) →